Search clinical trials for: ciclesonide

Total 87 results

ANRS, Emerging Infectious Diseases
Institut National de la Santé Et de la Recherche Médicale, France; University... and other collaborators

Recruiting

Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection (COVERAGE-A)

Covid19 | SARS-CoV2 Infection | Severe Acute Respiratory Syndrome Coronavirus 2 | Covid19 Drug Treatment

Burkina Faso, Guinea
Cambridge University Hospitals NHS Foundation Trust
GlaxoSmithKline; National Institute for Health Research, United Kingdom; Kidney... and other collaborators

Recruiting

PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V (PROTECT-V)

Covid19

United Kingdom
Hvidovre University Hospital

Recruiting

Periostin-guided Withdrawal of Inhaled Corticosteroids in Patients With Non-eosinophilic Asthma

Asthma

Denmark
Covis Pharma S.à.r.l.

Completed

Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)

Allergic Rhinitis

United States
Covis Pharma S.à.r.l.

Completed

A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients

COVID-19

United States
McGill University Health Centre/Research Institute...

Terminated

Inhaled Ciclesonide for Outpatients With COVID19 (CONTAIN)

COVID 19

Canada
University of Wisconsin, Madison
The V Foundation for Cancer Research

Terminated

ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer

Triple Negative Breast Cancer

United States
University Hospital, Bordeaux
University of Bordeaux

Completed

Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation (COVERAGEFrance)

Corona Virus Infection | Sars-CoV2

France
Ola Blennow, MD, PhD
Karolinska University Hospital; Danderyd Hospital; Centrallasarettet Västerås

Active, not recruiting

Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19) (HALT)

Pneumonia, Viral | Covid-19 | Sars-CoV2

Sweden
Korea University Guro Hospital

Completed

A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19

COVID-19

Korea, Republic of
West Penn Allegheny Health System

Completed

Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic Rhinitis

Asthma | Allergic Rhinitis

United States
Mansoura University

Completed

Analgesia of Erector Spinae Plane Block Versus Quadratus Lumborum Block

Colorectal Cancer

Egypt
Cantonal Hosptal, Baselland

Completed

The Mannitol-Asthma-Ciclesonide-Study (MACS)

Asthma, Bronchial
USDA Beltsville Human Nutrition Research Center

Completed

Novel Metabolites of Beta-Carotene and Lycopene

Healthy

United States
Texas Tech University Health Sciences Center, El...

Withdrawn

Regulating Urine pH Levels to Alleviate Chronic Joint Pain

Arthritis

United States
AstraZeneca

Completed

Efficacy of Ciclesonide Inhaled Once Daily Versus Other Corticosteroids Used for Treatment of Mild Asthma in Children (4 to 11 Years) (BY9010/CA-101) (POPCICLE)

Asthma

Canada, Hungary, South Africa
AstraZeneca

Completed

Effect of High Dose Ciclesonide on Asthma Control (CONTRAST)

Bronchial Asthma

Germany, Israel, Brazil, Russian Federation, Argentina
AstraZeneca

Completed

Efficacy and Safety of Ciclesonide Nasal Spray in Participants With Seasonal Allergic Rhinitis (SAR) in Russia

Seasonal Allergic Rhinitis

Russian Federation
AstraZeneca

Completed

Responsiveness of Lower Airways in Adult Patients (18-60 Years) With Stable Asthma After Treatment With Ciclesonide and Fluticasone Propionate (BY9010/NL-101)

Asthma

Netherlands
AstraZeneca
Nycomed GmbH

Completed

A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children (6-11 Years) With Asthma (RAINBOW)

Asthma

Hungary, South Africa, Russian Federation, Spain, Poland, Germany, Bulgaria, Romania, Ukraine
AstraZeneca

Completed

Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma.

Asthma

Russian Federation, Hungary, South Africa, Mexico, United States, Poland
AstraZeneca

Completed

Asthma Care With Alvesco® (Ciclesonide) in Primary Care in Adults - The ACCEPT-study (BY9010/CA-102)

Asthma

Canada
AstraZeneca

Completed

Efficacy of Ciclesonide on Small Airways in Patients With Stable Asthma (18 to 60 y) (BY9010/M1-131)

Asthma

Netherlands
AstraZeneca

Completed

Efficacy and Safety of Ciclesonide in Preschool Children With Asthma (2 to 6 Years) (BY9010/M1-207)

Asthma

Hungary, South Africa, Germany, Brazil, India, Spain, Netherlands, Poland, Switzerland
AstraZeneca

Completed

Efficacy of Ciclesonide Versus Fluticasone Propionate in Patients With Mild to Moderate Asthma (12 to 75 y) (BY9010/M1-142)

Asthma

Germany, South Africa, Austria, Canada, Poland
AstraZeneca

Completed

Effect of Inhaled Ciclesonide in Adult Patients With Asthma (BY9010/M1-125)

Asthma

United Kingdom
AstraZeneca

Completed

Effect of Inhaled Ciclesonide Versus Fluticasone Propionate in Patients With Mild to Moderate Asthma (18 to 65 y) (BY9010/M1-129)

Asthma

Belgium
AstraZeneca

Completed

Safety and Tolerability of Ciclesonide and Formoterol Fumarate Inhaled Once Daily in Patients With Asthma (18 to 75 y) (BY9010/M1-506)

Asthma

France, Germany, Hungary, South Africa
AstraZeneca

Completed

Efficacy, Safety & Tolerability of Ciclesonide 200mcg Spray 4 Weeks Treatment for Intermittent & Persistent Rhinitis (SISRIP)

Seasonal Rhinitis | Perennial Rhinitis

Mexico
AstraZeneca

Completed

Efficacy of Ciclesonide During the Cold Season in Patients Older Than 12 Years With Persistent Asthma (ARTIST)

Asthma

Germany
AstraZeneca

Completed

Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602)

Rhinitis, Allergic, Seasonal

United States
AstraZeneca

Completed

Efficacy of Ciclesonide Inhaled Once Daily Versus Fluticasone Propionate Inhaled Twice Daily in Children With Asthma (6 to 11 y) (BY9010/M1-206)

Asthma

South Africa, Germany, Brazil, Hungary, Poland, Portugal
AstraZeneca

Completed

Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409)

Allergic Rhinitis | Perennial Allergic Rhinitis | Hay Fever

United States
AstraZeneca

Completed

Effect of Ciclesonide on Quality of Life in Patients With Moderate Persistent Asthma (21 to 65 y) (BY9010/AR-101)

Asthma

Argentina
AstraZeneca

Completed

ATEM (Alvesco Non-interventional Study) (ATEM)

Asthma | Allergy

Austria
AstraZeneca

Completed

Efficacy of Ciclesonide and Fluticasone Propionate in Adult Patients With Moderate and Severe Persistent Asthma (18 to 75 y) (BY9010/IT-101)

Asthma

United Kingdom, Switzerland, Belgium, France, Italy, Spain, Netherlands
AstraZeneca

Completed

To Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, in the Treatment of Perennial Allergic Rhinitis in Pediatrics (BY9010/M1-405)

Rhinitis, Allergic, Perennial | Hay Fever

United States
AstraZeneca

Completed

Study Using the Environmental Exposure Unit (EEU) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-407)

Rhinitis, Allergic, Seasonal | Hay Fever

Canada
AstraZeneca

Completed

Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403)

Allergic Rhinitis | Perennial Allergic Rhinitis | Hay Fever

United States, Canada
AstraZeneca

Completed

Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in Treatment of Seasonal Allergic Rhinitis (BY9010/M1-406)

Rhinitis, Allergic, Seasonal | Hay Fever

Canada
AstraZeneca

Completed

To Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-401)

Rhinitis, Allergic, Seasonal | Hay Fever

United States
AstraZeneca

Completed

To Assess the Safety and Efficacy of Ciclesonide Applied as a Nasal Spray in the Treatment of Perennial Allergic Rhinitis (BY9010/M1-402)

Rhinitis, Allergic, Perennial

United States
AstraZeneca

Completed

Ciclesonide for the Treatment of Airway Hyperresponsiveness

Asthma

Switzerland
AstraZeneca

Completed

Efficacy of Ciclesonide Inhaled Once Daily Versus Fluticasone Propionate Inhaled Twice Daily in Children With Asthma (4 to 15 y) (BY9010/M1-205)

Asthma

India
AstraZeneca

Completed

Effects of Inhaled Ciclesonide Versus Fluticasone Propionate Versus Placebo on Lower Leg Growth in Prepubertal Children With Mild Persistent Asthma (6 to 12 y) (BY9010/M1-208)

Asthma

Denmark
AstraZeneca

Completed

Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Beclomethasone Dipropionate (HFA-BDP) in Patients With Perennial Allergic Rhinitis (PAR) (BY9010/M1-408)

Rhinitis, Allergic, Perennial

United States
AstraZeneca

Completed

Effectiveness of Ciclesonide Versus Budesonide in Patients With Asthma (18 to 75 y) (BY9010/M1-136)

Asthma

Korea, Republic of
AstraZeneca

Completed

Efficacy and Safety of Ciclesonide Administered With or Without Different Spacers in Patients With Asthma (12 to 75 y) (BY9010/M1-145)

Asthma

Germany, Hungary, India, Italy, Canada, France
AstraZeneca

Completed

A Study of Ciclesonide Nasal Spray in Patients 18 Years and Older With Seasonal Allergic Rhinitis (BY9010/M1-413)

Rhinitis, Allergic, Seasonal | Hay Fever

Canada
AstraZeneca

Completed

Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)

Seasonal Allergic Rhinitis | Hay Fever

United States

3

Subscribe